Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice
FEBS Open Bio · 2026
DOI: 10.1002/2211-5463.70265 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2026. Verfasst von Jade Gauvin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Université de Montréal, Canada. Hauptthemen laut MEDLINE: Myocardial Reperfusion Injury, CD36 Antigens, Fatty Acids, Peptides, Cyclic. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Natural Sciences and Engineering Research Council of Canada, Heart and Stroke Foundation of Canada.
Abstract (Originalsprache)
Ischemic heart disease remains a leading global cause of death. We investigated the cardioprotective effects of the selective cluster of differentiation‐36 receptor (CD36) modulator azapeptide MPE‐298 in a mouse model of myocardial ischemia–reperfusion. Given before reperfusion, a single intravenous dose of azapeptide MPE‐298 reduced infarct size by 44% of the area‐at‐risk and transiently decreased left ventricular long‐chain fatty acids (LCFA) accumulation, independently of saturation status. Metabolomic profiling identified changes in amino acids that may fuel the tricarboxylic acid cycle and provide substrates for glutathione‐dependent antioxidant defense. Gene expression analysis showed transient modulation of oxidative stress and inflammation‐associated genes in both heart and adipose tissue. Thus, we conclude that modulation of CD36 by azapeptide MPE‐298 exhibits therapeutic potential for treating acute myocardial ischemia and reperfusion by supporting metabolic recovery and limiting excess LCFA uptake.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Université de Montréal, Canada.
- Metabolomics Platform, Research Center, Montreal Heart Institute, Université de Montréal, Canada.
- Department of Chemistry, Université de Montréal, Canada.
- Division of Endocrinology, Department of Medicine, Université de Sherbrooke, Centre de Recherche du CHUS, Canada.
- Faculty of Medicine, Department of Nutrition, Université de Montréal, Canada.
- Institute for Research in Immunology and Cancer, Université de Montréal, Canada.
ORCID-Profile: Jade Gauvin, Sylvie Marleau, Simon-Pierre Gravel
Förderung
- CIHR
- Natural Sciences and Engineering Research Council of Canada
- Heart and Stroke Foundation of Canada
- Fonds de Recherche du Québec - Santé
- Fonds de recherche du Québec - Nature et technologies
- Canadian Institutes of Health Research
- Nature et technologies
Zitieren
APA
Gauvin, J., Radmannia, N., Huynh, D. N., Ménard, L., Daneault, C., Veilleux, M., Ahsanullah, A., Carpentier, A. C., Lubell, W. D., Ruiz, M., Ong, H., Marleau, S., & Gravel, S. P. (2026). Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70265
Vancouver
Gauvin J, Radmannia N, Huynh DN, Ménard L, Daneault C, Veilleux M, et al. Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice. FEBS Open Bio. 2026. doi:10.1002/2211-5463.70265
BibTeX
@article{Gauvin2026,
author = {Gauvin, Jade and Radmannia, Naghme and Huynh, David N and Ménard, Liliane and Daneault, Caroline and Veilleux, Maïté and Ahsanullah, Ahsanullah and Carpentier, André C and Lubell, William D and Ruiz, Matthieu and Ong, Huy and Marleau, Sylvie and Gravel, Simon-Pierre},
title = {Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice},
journal = {FEBS Open Bio},
year = {2026},
doi = {10.1002/2211-5463.70265}
}
EUVIMED